New hope to stop dangerous transplant complication
NCT ID NCT04572815
Summary
This trial is testing if a drug called ustekinumab can prevent a serious complication called graft-versus-host disease (GVHD) after a stem cell transplant for blood cancers. About 116 patients will receive either the drug or a placebo alongside their standard transplant care. The goal is to see if calming the immune system with this drug can stop the donor cells from attacking the patient's body.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC AND LYMPHOID SYSTEM NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Comprehensive Cancer Center,
Duarte, California, 91010, United States
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
-
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida, 33612, United States
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
Conditions
Explore the condition pages connected to this study.